Robert Alpern, MD
Ensign Professor of Medicine (Nephrology) and Professor of Cellular and Molecular PhysiologyCards
Administrative Support
Publications Overview
- 147 Publications
- 6,127 Citations
- 2 Yale Co-Authors
Education
University of Chicago (1976)
Northwestern University (1972)
Administrative Support
Publications Overview
- 147 Publications
- 6,127 Citations
- 2 Yale Co-Authors
Education
University of Chicago (1976)
Northwestern University (1972)
Administrative Support
Publications Overview
- 147 Publications
- 6,127 Citations
- 2 Yale Co-Authors
Education
University of Chicago (1976)
Northwestern University (1972)
About
Titles
Ensign Professor of Medicine (Nephrology) and Professor of Cellular and Molecular Physiology
Biography
Dr. Robert J. Alpern attended undergraduate school at Northwestern University, where he majored in Chemistry. He received his M.D. degree from the University of Chicago Pritzker School of Medicine in 1976, and received residency training in Internal Medicine at Columbia Presbyterian Hospital in New York. Following this, he performed a postdoctoral fellowship in Nephrology in the Cardiovascular Research Institute at the University of California, San Francisco. In 1982, Dr. Alpern joined the faculty at the University of California, San Francisco, and in 1987 he was recruited to the University of Texas Southwestern Medical Center as Chief of the Division of Nephrology. At Southwestern Dr. Alpern held the Ruth W. and Milton P. Levy, Sr. Chair in Molecular Nephrology and the Atticus James Gill, M.D. Chair in Medical Science. In July 1998 Dr. Alpern was appointed Dean of Southwestern Medical School and in June 2004, he moved to the Yale School of Medicine to become the Ensign Professor of Medicine and Dean of the medical school. Dr. Alpern’s research has focused on the regulation of kidney transport proteins. In addition Dr. Alpern has been highly committed to teaching and clinical medicine. In 2000 he was elected President of the American Society of Nephrology. He was elected to the American Society of Clinical Investigation, the Association of American Physicians , and the National Academy of Medicine, and has served on the Advisory Council of the National Institute of Diabetes and Digestive and Kidney Diseases.
Appointments
Nephrology
ProfessorPrimaryCellular & Molecular Physiology
ProfessorSecondary
Other Departments & Organizations
- Cellular & Molecular Physiology
- Internal Medicine
- Nephrology
- Yale Institute for Global Health
- Yale Ventures
Education & Training
- Postdoctoral Fellowship
- University of California, San Francisco (1982)
- Resident
- Columbia Presbyterian Hospital (1979)
- MD
- University of Chicago (1976)
- BA
- Northwestern University (1972)
Board Certifications
Nephrology
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 1982
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 1979
Research
Overview
Dr. Alpern’s research has focused on the regulation of kidney transport proteins.
Medical Research Interests
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Pat Preisig, PhD
Xuefei Tian, MD
Kidney
Acid-Base Equilibrium
Acidosis, Renal Tubular
Renal Circulation
Nephrology
Urination
Publications
2022
Metabolic Alkalosis
Krishnan N, Alpern R. Metabolic Alkalosis. Nephrology Self-Assessment Program 2022, 20: 145-159. DOI: 10.1681/nsap.2022.20.2.6.Peer-Reviewed Original ResearchCitations
2018
Use of Renin Angiotensin System Blockers After Acute Kidney Injury: Balancing Tradeoffs.
Alpern RJ, Peixoto AJ. Use of Renin Angiotensin System Blockers After Acute Kidney Injury: Balancing Tradeoffs. JAMA Internal Medicine 2018, 178: 1690-1692. PMID: 30422208, DOI: 10.1001/jamainternmed.2018.4757.Peer-Reviewed Original ResearchCitationsAltmetricDonald Seldin: A Transformative Leader in Medicine and Nephrology
Alpern R, Giebisch G. Donald Seldin: A Transformative Leader in Medicine and Nephrology. Journal Of The American Society Of Nephrology 2018, 29: 2029-2030. PMID: 29986871, PMCID: PMC6065072, DOI: 10.1681/asn.2018060603.Peer-Reviewed Original ResearchAltmetricAcid Stimulation of the Citrate Transporter NaDC-1 Requires Pyk2 and ERK1/2 Signaling Pathways
Zacchia M, Tian X, Zona E, Alpern RJ, Preisig PA. Acid Stimulation of the Citrate Transporter NaDC-1 Requires Pyk2 and ERK1/2 Signaling Pathways. Journal Of The American Society Of Nephrology 2018, 29: 1720-1730. PMID: 29678998, PMCID: PMC6054333, DOI: 10.1681/asn.2017121268.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAcidsAmmonium ChlorideAnimalsCells, CulturedCitric AcidCSK Tyrosine-Protein KinaseDicarboxylic Acid TransportersEndothelin-1Epithelial CellsFocal Adhesion Kinase 2Kidney Tubules, ProximalMAP Kinase Signaling SystemMiceMice, KnockoutMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3OpossumsOrganic Anion Transporters, Sodium-DependentPhosphorylationProto-Oncogene Proteins c-rafReceptor, Endothelin BRibosomal Protein S6 Kinases, 90-kDaSrc-Family KinasesTransfectionConceptsET-1/ETEndothelin-1Proximal tubulesCultured opossum kidney cellsAcid stimulationInhibition of Pyk2ET-1 stimulationRenal proximal tubulesNaDC-1Opossum kidney cellsCl loadingC-SrcPhosphorylation of Raf1Urine citratePyk2 knockdownEnd pointAcid loadApical NaERK1/2 pathwayStimulationMiceKidney cellsKidneyPyk2ERK1/2
2017
Randomized, Controlled Trial of TRC101 to Increase Serum Bicarbonate in Patients with CKD
Bushinsky DA, Hostetter T, Klaerner G, Stasiv Y, Lockey C, McNulty S, Lee A, Parsell D, Mathur V, Li E, Buysse J, Alpern R. Randomized, Controlled Trial of TRC101 to Increase Serum Bicarbonate in Patients with CKD. Clinical Journal Of The American Society Of Nephrology 2017, 13: 26-35. PMID: 29102959, PMCID: PMC5753317, DOI: 10.2215/cjn.07300717.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsSerum bicarbonateEnd of treatmentMetabolic acidosisTreatment groupsBaseline serum bicarbonateMean baseline eGFRMEq/LSignificant adverse effectsBaseline eGFRGastrointestinal eventsAdverse eventsFirst doseControlled TrialsHeart failurePatientsCKDBaseline levelsMean increaseAbstractTextUnit studiesAcidosisAdverse effectsPlaceboTreatmentDays
2015
Research in academic medical centers: Two threats to sustainable support
Levine AS, Alpern RJ, Andrews NC, Antman K, Balser JR, Berg JM, Davis PB, Fitz JG, Golden RN, Goldman L, Jameson JL, Lee VS, Polonsky KS, Rappley MD, Reece EA, Rothman PB, Schwinn DA, Shapiro LJ, Spiegel AM. Research in academic medical centers: Two threats to sustainable support. Science Translational Medicine 2015, 7: 289fs22-289fs22. PMID: 26019216, DOI: 10.1126/scitranslmed.aac5200.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and Concepts
2013
Treatment of Severe Metabolic Alkalosis in a Patient With Congestive Heart Failure
Peixoto AJ, Alpern RJ. Treatment of Severe Metabolic Alkalosis in a Patient With Congestive Heart Failure. American Journal Of Kidney Diseases 2013, 61: 822-827. PMID: 23481366, DOI: 10.1053/j.ajkd.2012.10.028.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCongestive heart failureHeart failureMetabolic alkalosisLow bicarbonate dialysisRenal bicarbonate excretionRenin-angiotensin systemSevere metabolic alkalosisDistal sodium deliveryCommon acid-base disorderAcid-base disordersDiuretic regimenDiuretic therapyAldosterone antagonistsNeurohormonal activationCirculatory failureBicarbonate excretionKidney failurePotassium repletionSodium deliveryBase excessUrine acidificationAppropriate managementAlkalosisDisease statesBicarbonate retentionChapter 38 Pathophysiology of Sodium Retention and Wastage
Palmer B, Alpern R, Seldin D. Chapter 38 Pathophysiology of Sodium Retention and Wastage. 2013, 1283-1317. DOI: 10.1016/b978-0-12-381462-3.00038-0.Peer-Reviewed Original ResearchCitationsChapter 58 Clinical Syndromes of Metabolic Alkalosis
Moe O, Alpern R, Seldin D. Chapter 58 Clinical Syndromes of Metabolic Alkalosis. 2013, 2021-2047. DOI: 10.1016/b978-0-12-381462-3.00058-6.Peer-Reviewed Original ResearchCitationsChapter 59 Clinical Syndromes of Metabolic Acidosis
Krapf R, Seldin D, Alpern R. Chapter 59 Clinical Syndromes of Metabolic Acidosis. 2013, 2049-2111. DOI: 10.1016/b978-0-12-381462-3.00059-8.Peer-Reviewed Original ResearchCitationsConceptsMetabolic acidosisDivalent ion metabolismMaladaptive renal responseUrine anion gapAcute metabolic acidosisNegative nitrogen balanceAcid-base disturbancesBlood buffer capacitySecondary hypocapniaClinical sequelaeRenal responseChronic settingClinical syndromeVentilatory responseBone metabolismBone massAnion gapPrimary decreaseSevere formDiagnostic criteriaBone qualitySecondary decreaseAcidosisElectrolyte changesClinical setting
Academic Achievements & Community Involvement
honor John P. Peters Award
National AwardAmerican Society of NephrologyDetails01/01/2008United Stateshonor National Academy of Medicine
National AwardDetails01/01/2007honor NIH Merit Award
National AwardDetails01/01/1995United Stateshonor Association of American Physicians
National AwardAssociation of American PhysiciansDetails01/01/1993United Stateshonor American Society of Clinical Investigation
National AwardAmerican Society of Clinical InvestigationDetails01/01/1987United States
News
News
- October 15, 2024
Meet Lonnette Diggs, Research Associate II, Nephrology
- April 25, 2024
Portrait Unveiling Honors Former Dean Robert J. Alpern
- November 15, 2022
Meet Yale Internal Medicine: Madhav C. Menon, MBBS, MD
- September 29, 2022
Debt-free Medical Education: YSM’s Vision for the Future